Grufity logoGrufity logo

Oragenics Inc Stock Research

OGEN

7.16USD-0.01(-0.14%)Delayed

Market Summary

USD7.16-0.01
Delayed
-0.14%

OGEN Stock Price

OGEN RSI Chart

OGEN Valuation

Market Cap

14.0M

Price/Earnings (Trailing)

-0.86

Price/Sales (Trailing)

267.61

EV/EBITDA

0

Price/Free Cashflow

-0.91

OGEN Price/Sales (Trailing)

OGEN Profitability

EBT Margin

-18410.97%

Return on Equity

-122.04%

Return on Assets

-108.23%

Free Cashflow Yield

-110.03%

OGEN Fundamentals

OGEN Revenue

OGEN Earnings

Earnings (TTM)

-16.3M

Earnings Y/Y

10.63%

Earnings Q/Q

2.85%

Price Action

52 Week Range

0.109.29
(Low)(High)

Last 7 days

4942.3%

Last 30 days

4837.9%

Last 90 days

3342.3%

Trailing 12 Months

1619.1%

OGEN Financial Health

Current Ratio

9.69

OGEN Investor Care

Shares Dilution (1Y)

0.90%

Peers (Alternatives to Oragenics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
363.1B
1.2B
17.99% 7.19%
-172.5
290.49
17.64% -57.08%
263.1B
57.8B
-9.45% 14.91%
19.62
4.55
4.80% 77.95%
80.0B
8.7B
8.24% 36.52%
24.45
9.2
22.03% 50.41%
78.0B
15.0B
0.10% 17.05%
14.53
5.14
21.25% -23.23%
28.4B
960.9M
-4.12% 67.08%
-23.99
29.51
28.24% -41.08%
11.8B
1.9B
-6.60% 28.83%
16.67
6.34
12.37% 52.98%
11.3B
876.0M
-1.22% 90.74%
-15.73
12.86
35.70% -47.34%
MID-CAP
5.2B
504.0K
11.86% 385.71%
-19.04
2.5K
-66.53% -15.89%
3.0B
343.4M
-0.07% -36.01%
-4.42
8.74
-4.50% -90.69%
2.8B
272.3M
8.65% -33.63%
-3.88
10.22
-18.36% -74.56%
2.8B
-
15.87% -57.36%
-3.74
917.1
- -52.72%
1.5B
191.8M
-15.20% 185.31%
22.95
8.01
43.59% 60.82%
SMALL-CAP
360.8M
93.0M
4.88% -51.33%
-1.89
3.88
-19.83% -30.37%
17.5M
-
17.65% -70.22%
-0.42
19.11
-77.61% 5.14%
4.0M
-
-5.35% 37.11%
-0.01
63.29
26.15% -23.38%

Financials for Oragenics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
RevenueNaN%nullnullnull86,987284,455
Operating Expenses-2.1%16,574,83616,929,68416,690,13615,858,0058,920,882
  S&GA Expenses8.6%4,668,6504,300,7754,626,8345,271,8615,390,574
  R&D Expenses-5.7%11,906,18612,628,90912,063,30210,586,14412,628,350
EBITDA2.8%-16,225,900.00-16,693,284.00-16,473,649.00-15,654,621.00-
EBITDA Margin32.8%-183.55-273.05-179.97--
Earnings Before Taxes2.8%-16,278,306.00-16,744,409.00-16,527,063.00-15,711,614.00-17,828,121.00
EBT Margin32.8%-184.11-273.94-180.62--
Interest Expenses-11.3%14,39216,21716,43415,75614,861
Net Income2.8%-16,278,306.00-16,744,409.00-16,527,063.00-15,711,614.00-17,828,121.00
Net Income Margin32.8%-184.11-273.94-180.62--
Free Cahsflow8.6%-14,823,906.00-16,226,594.00-14,910,658.00-13,514,088.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-18.5%1518222831
  Current Assets-19.2%1518222831
    Cash Equivalents-21.9%1418212730
  Net PPE20.6%00000
  Current Liabilities2.6%11112
Shareholder's Equity-20.5%1317212629
  Retained Earnings-2.2%-185.26-181.34-177.31-171.27-168.98
  Additional Paid-In Capital0.8%197195195195195
Accumulated Depreciation-2----
Shares Outstanding0.8%22222
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations5.0%-15,280.24-16,084.19-14,779.73-13,470.21-14,617.20
  Share Based Compensation52.4%1,0707026551,6881,730
Cashflow From Investing-4.3%-131.83-126.40-189.60-43.88-32.16
Cashflow From Financing-16.2%-585.76-504.17-229.7323,14034,547

Risks for OGEN

What is the probability of a big loss on OGEN?

100%


Probability that Oragenics stock will be more than 20% underwater in next one year

100%


Probability that Oragenics stock will be more than 30% underwater in next one year.

97.7%


Probability that Oragenics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Oragenics was unfortunately bought at previous high price.

Drawdowns

Returns for OGEN

Cumulative Returns on OGEN

-12.8%


10-Year Cumulative Returns

-4.5%


7-Year Cumulative Returns

20.1%


5-Year Cumulative Returns

150.7%


3-Year Cumulative Returns

What are the long-term rolling returns for OGEN?

FIve years rolling returns for Oragenics.

Annualized Returns

Which funds bought or sold OGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-23
LexAurum Advisors, LLC
unchanged
-
-5,745
5,255
-%
2023-01-20
Newman Dignan & Sheerar, Inc.
unchanged
-
-900
1,100
-%
2023-01-19
TSFG, LLC
sold off
-100
-1,000
-
-%
2023-01-18
Verition Fund Management LLC
sold off
-100
-3,000
-
-%
2023-01-11
Sara-Bay Financial
reduced
-36.69
-322,000
134,000
0.07%
2022-11-15
STATE STREET CORP
unchanged
-
-60,000
112,000
-%
2022-11-15
JANE STREET GROUP, LLC
added
61.09
1,000
13,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
2022-11-14
BlackRock Inc.
reduced
-0.15
-160,000
302,000
-%
2022-11-14
NORTHERN TRUST CORP
unchanged
-
-22,000
41,000
-%

1–10 of 32

Latest Funds Activity

Are funds buying OGEN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own OGEN
No. of Funds

Oragenics News

ETF Daily News

Pan African Resources (LON:PAF) Stock Price Crosses Below 200 ....

ETF Daily News,
30 hours ago

Marketscreener.com

InvestorsObserver

Investing.com UK

Armenian Reporter

Benzinga

Marketscreener.com

Schedule 13G FIlings of Oragenics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 29, 2021
intracoastal capital, llc
1.6%
1,491,667
SC 13G/A
Jan 26, 2021
hernandez joseph
0%
0
SC 13D/A
Oct 08, 2020
kirk randal j
0.4%
230,792
SC 13D/A
May 15, 2020
hernandez joseph
16.6%
9,200,000
SC 13D
Mar 02, 2020
kirk randal j
9.9%
4,612,166
SC 13D/A
Feb 14, 2020
anson funds management lp
4.9%
2,422,511
SC 13G/A
Feb 11, 2020
intracoastal capital, llc
6.7%
3,333,334
SC 13G/A
Feb 10, 2020
cvi investments, inc.
4.9%
2,422,511
SC 13G/A
Jan 24, 2020
koski family lp
3.4%
1,628,419
SC 13D/A

OGEN Fair Value

Recent SEC filings of Oragenics

View All Filings
Date Filed Form Type Document
Jan 23, 2023
8-K
Current Report
Jan 13, 2023
S-3
S-3
Jan 03, 2023
4
Insider Trading
Dec 23, 2022
8-K
Current Report
Dec 22, 2022
8-K
Current Report
Dec 20, 2022
8-K
Current Report
Dec 19, 2022
8-K
Current Report
Dec 16, 2022
4
Insider Trading
Dec 16, 2022
8-K
Current Report
Dec 15, 2022
4
Insider Trading

Latest Insider Trading transactions for OGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-30
KOSKI ROBERT C
sold
-4,468.66
0.1055
-42,357
-
2022-12-29
KOSKI ROBERT C
sold
-3,884.69
0.106
-36,648
-
2022-12-15
KOSKI ROBERT C
sold
-24,699.4
0.1758
-140,497
-
2022-12-14
KOSKI ROBERT C
sold
-788.025
0.175
-4,503
-
2022-12-14
KOSKI ROBERT C
sold
-4,375
0.175
-25,000
-
2022-12-09
KOSKI ROBERT C
sold
-9,612.62
0.197
-48,795
-
2022-12-08
KOSKI ROBERT C
sold
-2,607.2
0.2
-13,036
-
2022-11-30
KOSKI ROBERT C
sold
-38,220
0.1911
-200,000
-
2022-11-29
KOSKI ROBERT C
sold
-38,460
0.1923
-200,000
-
2022-06-17
Telling Fred
bought
2,884.02
0.286
10,084
-

1–10 of 38

Michael O. Sullivan
5
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Income Statement

2022-09-30
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Grant revenue$ 86,047$ 131,521
Operating expenses:    
Research and development2,824,5983,547,32110,595,8429,275,800
General and administrative1,215,009847,1343,590,8924,194,103
Total operating expenses4,039,6074,394,45514,186,73413,469,903
Loss from operations(3,953,560)(4,394,455)(14,055,213)(13,469,903)
Other income (expense):    
Interest income41,63417,76068,90962,047
Interest expense(5,228)(7,053)(9,290)(10,654)
Local business tax(489)2(1,469)(1,198)
Miscellaneous income11,333670
Total other income, net35,91710,70969,48350,865
Loss before income taxes(3,917,643)(4,383,746)(13,985,730)(13,419,038)
Income tax benefit
Net loss$ (3,917,643)$ (4,383,746)$ (13,985,730)$ (13,419,038)
Basic and diluted net loss per share$ (0.03)$ (0.04)$ (0.12)$ (0.12)
Shares used to compute basic and diluted net loss per share116,744,807116,262,938116,511,473111,748,586

OGEN Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 13,951,054$ 27,265,703
Other receivables6,987
Prepaid expenses and other current assets561,952434,699
Total current assets14,513,00627,707,389
Property and equipment, net132,38245,708
Operating lease right-of-use assets395,435477,882
Total assets15,040,82328,230,979
Current liabilities:  
Accounts payable and accrued expenses871,084947,574
Short-term notes payable424,924303,416
Operating lease liabilities201,973194,270
Total current liabilities1,497,9811,445,260
Long-term liabilities:  
Operating lease liabilities204,593299,520
Total long-term liabilities204,593299,520
Shareholders’ equity:  
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000, and 9,417,000 Series A shares, 4,050,000 and 6,600,000 Series B shares, issued and outstanding at September 30, 2022 and December 31, 2021, respectively1,592,7232,656,713
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively, 117,304,809 and 116,394,806 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively117,305116,395
Additional paid-in capital196,888,079194,987,219
Accumulated deficit(185,259,858)(171,274,128)
Total shareholders’ equity13,338,24926,486,199
Total liabilities and shareholders’ equity$ 15,040,823$ 28,230,979